Kabra Drugs Secures Letter of Intent from Chhattisgarh Government for ₹200 Crore Pharmaceutical Manufacturing Project
Kabra Drugs Ltd has received a Letter of Intent (LOI) from the Government of Chhattisgarh regarding the proposed establishment of a pharmaceutical manufacturing facility in Nava Raipur Pharma Park, Chhattisgarh. This development is set to significantly bolster the company's operational capabilities and support its long-term growth strategy.The LOI was received on June 12, 2026. The project involves an investment estimated at approximately ₹200 Crore. This proposed venture aims to expand the company’s manufacturing footprint and enhance its overall industrial capacity.
The planned facility includes related healthcare manufacturing activities at Nava Raipur Pharma Park. Furthermore, the project is expected to generate around 250 direct and indirect employment opportunities upon implementation.
Details regarding the proposed investment, the partnering authority, and the project scope are summarized below:
| Particulars | Details |
|---|---|
| Authority | Government of Chhattisgarh |
| Nature of Action | Receipt of Letter of Intent (LOI) for a pharmaceutical manufacturing project |
| Date of LOI Receipt | June 12, 2026 |
| Project Scope | Establishment of pharmaceutical and healthcare manufacturing facility |
| Proposed Investment | Approximately ₹200 Crore |
| Location | Nava Raipur Pharma Park, Chhattisgarh |
| Employment Generation | Approximately 250 direct and indirect opportunities |
The planned investment is conditional upon the execution of definitive agreements, receipt of all necessary approvals and sanctions, incentives, and compliance requirements as mandated from time to time. The project's expected benefits include strengthening operational capabilities and promoting long-term business growth for Kabra Drugs Ltd.
Stock Price Movement
At the close on Friday, Kabra Drugs Ltd. saw its shares settle at ₹23.63, recording a healthy 10.27% jump. The stock moved within an intraday range that spanned from a low of ₹21.75 to a high of ₹25.02.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.